Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.65)
# 188
Out of 5,150 analysts
144
Total ratings
52.38%
Success rate
43.53%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Downgrades: Neutral | $28 → $14 | $13.67 | +2.45% | 2 | Mar 4, 2026 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $105 → $150 | $71.11 | +110.94% | 4 | Feb 23, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $90 → $108 | $62.27 | +73.44% | 6 | Jan 21, 2026 | |
| IRD Opus Genetics | Initiates: Buy | $9 | $4.57 | +96.94% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $26.70 | +57.30% | 2 | Dec 1, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $30 → $40 | $25.23 | +58.54% | 2 | Nov 21, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $12 | $4.74 | +153.16% | 1 | Nov 19, 2025 | |
| NVAX Novavax | Reiterates: Buy | $18 → $16 | $9.89 | +61.78% | 20 | Nov 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $39.22 | +88.68% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $434.80 | +28.79% | 13 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $29.19 | +88.42% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.05 | +555.74% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $4.27 | +321.55% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.44 | +247.22% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $2.08 | +44.23% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.76 | +163.16% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $12.92 | +54.80% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.95 | +53.85% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $20.37 | +71.82% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $65.10 | -41.63% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $32.14 | +198.69% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.06 | +41.51% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $8.73 | +1,503.67% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.50 | +2,471.43% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.20 | +4,900.00% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $2.57 | +94.55% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.21 | +1,890.95% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $3.10 | +2,803.23% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.32 | +430.30% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $0.96 | +469,383.57% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.45 | +186,106.90% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $7.58 | +915.83% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.59 | +244,964.67% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $3.11 | +28.62% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $85.48 | -54.38% | 2 | Mar 18, 2020 |
Theravance Biopharma
Mar 4, 2026
Downgrades: Neutral
Price Target: $28 → $14
Current: $13.67
Upside: +2.45%
Nektar Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $105 → $150
Current: $71.11
Upside: +110.94%
Cytokinetics
Jan 21, 2026
Maintains: Buy
Price Target: $90 → $108
Current: $62.27
Upside: +73.44%
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $4.57
Upside: +96.94%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $26.70
Upside: +57.30%
Zymeworks
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $25.23
Upside: +58.54%
Nuvation Bio
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $4.74
Upside: +153.16%
Novavax
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $9.89
Upside: +61.78%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $39.22
Upside: +88.68%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $434.80
Upside: +28.79%
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $29.19
Upside: +88.42%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $3.05
Upside: +555.74%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $4.27
Upside: +321.55%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.44
Upside: +247.22%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $2.08
Upside: +44.23%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.76
Upside: +163.16%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $12.92
Upside: +54.80%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.95
Upside: +53.85%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $20.37
Upside: +71.82%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $65.10
Upside: -41.63%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $32.14
Upside: +198.69%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.06
Upside: +41.51%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $8.73
Upside: +1,503.67%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.50
Upside: +2,471.43%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.20
Upside: +4,900.00%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $2.57
Upside: +94.55%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.21
Upside: +1,890.95%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $3.10
Upside: +2,803.23%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.32
Upside: +430.30%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $0.96
Upside: +469,383.57%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.45
Upside: +186,106.90%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $7.58
Upside: +915.83%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.59
Upside: +244,964.67%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $3.11
Upside: +28.62%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $85.48
Upside: -54.38%